Reimbursement of Lung Cancer in Turkey: A 10-Year Single Center Study

IF 3.1 2区医学 Q2 ONCOLOGY

Cancer Medicine Pub Date : 2025-07-11 DOI:10.1002/cam4.71014

Kerem Ensarioğlu, Berna Akıncı Özyürek, Metin Dinçer, Hızır Alı Gümüşler

{"title":"Reimbursement of Lung Cancer in Turkey: A 10-Year Single Center Study","authors":"Kerem Ensarioğlu, Berna Akıncı Özyürek, Metin Dinçer, Hızır Alı Gümüşler","doi":"10.1002/cam4.71014","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective and Background</h3>\n \n <p>Lung cancer is the most common carcinoma reported worldwide. The burden of lung carcinoma on healthcare has been reported in many countries, while a real-life report within Turkey has yet to be published. This study aims to present the available results from a tertiary center specializing in pulmonology.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>The study's population consisted of 199.112 patient admissions, which were reimbursed under the national healthcare system. After exclusion criteria, 4.991 patients were evaluated in the study. The patient's demographic data, malignancy types, diagnostic methods for lung carcinoma type and staging, and treatment modalities were recorded.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The average healthcare expenditure during the treatment duration was 4289.4 (± 3739.4) USD, and the median was 3219.9 USD. The average expenditure was higher for male patients (3260 to 2977 USD, <i>p</i> = 0.003). Survivors had an overall lower healthcare expenditure than the non-survivor group (2865 to 4230 USD). Patients with locally advanced disease classification also had a higher expenditure on other stages (<i>p</i> < 0.001). This was not present in SCLC, as those diagnosed with SCLC had the most expenditure at the limited stage (<i>p</i> < 0.001). Carcinoid tumors had the least expenditure compared to other subtypes at limited and advanced stages (<i>p</i> < 0.001). SCLC had the highest expenditure requirement at the limited stage (<i>p</i> < 0.001). At the locally advanced stage, large cell carcinoma, SCC, and adenocarcinoma were the subtypes requiring the highest expenditure (<i>p</i> < 0.001).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The parameters affecting overall cost were age, gender, stage, and malignancy subtype. The healthcare expenditure was also affected by the difficulty of diagnosis, with the non-diagnostic patient group having an overall higher cost. A longer duration of hospitalization and treatment given on an inpatient basis also contributed to a higher cost of care.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 13","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71014","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.71014","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective and Background

Lung cancer is the most common carcinoma reported worldwide. The burden of lung carcinoma on healthcare has been reported in many countries, while a real-life report within Turkey has yet to be published. This study aims to present the available results from a tertiary center specializing in pulmonology.

Methods

The study's population consisted of 199.112 patient admissions, which were reimbursed under the national healthcare system. After exclusion criteria, 4.991 patients were evaluated in the study. The patient's demographic data, malignancy types, diagnostic methods for lung carcinoma type and staging, and treatment modalities were recorded.

Results

The average healthcare expenditure during the treatment duration was 4289.4 (± 3739.4) USD, and the median was 3219.9 USD. The average expenditure was higher for male patients (3260 to 2977 USD, p = 0.003). Survivors had an overall lower healthcare expenditure than the non-survivor group (2865 to 4230 USD). Patients with locally advanced disease classification also had a higher expenditure on other stages (p < 0.001). This was not present in SCLC, as those diagnosed with SCLC had the most expenditure at the limited stage (p < 0.001). Carcinoid tumors had the least expenditure compared to other subtypes at limited and advanced stages (p < 0.001). SCLC had the highest expenditure requirement at the limited stage (p < 0.001). At the locally advanced stage, large cell carcinoma, SCC, and adenocarcinoma were the subtypes requiring the highest expenditure (p < 0.001).

Conclusion

The parameters affecting overall cost were age, gender, stage, and malignancy subtype. The healthcare expenditure was also affected by the difficulty of diagnosis, with the non-diagnostic patient group having an overall higher cost. A longer duration of hospitalization and treatment given on an inpatient basis also contributed to a higher cost of care.

Abstract Image

查看原文本刊更多论文

土耳其肺癌报销：一项为期10年的单中心研究

目的与背景肺癌是世界范围内最常见的癌症。许多国家都报道了肺癌对医疗保健的负担，而土耳其境内的真实报告尚未发表。本研究的目的是报告一个专门从事肺科的三级中心的现有结果。方法研究对象为199.112例在国家医保制度下报销的住院患者。排除标准后，4991例患者被纳入研究。记录患者的人口统计学资料、恶性肿瘤类型、肺癌的诊断方法、分期及治疗方式。结果治疗期间平均医疗费用为4289.4（±3739.4）美元，中位数为3219.9美元。男性患者平均支出较高（3260 ~ 2977美元，p = 0.003）。幸存者的总体医疗保健支出低于非幸存者组（2865至4230美元）。局部疾病晚期患者在其他阶段的支出也较高（p < 0.001）。这在SCLC中不存在，因为那些被诊断为SCLC的患者在有限阶段的花费最多（p < 0.001）。与其他亚型相比，类癌肿瘤在有限和晚期的花费最少（p < 0.001）。SCLC在有限阶段的支出需求最高（p < 0.001）。在局部晚期，大细胞癌、SCC和腺癌是需要最高花费的亚型（p < 0.001）。结论影响总费用的因素有年龄、性别、分期、恶性肿瘤亚型。医疗保健支出也受到诊断困难的影响，未诊断的患者群体总体成本较高。住院时间较长和住院治疗时间较长也导致护理费用较高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.